The collaboration revenue of Intellia therapeutics in 2024 was around 58 million U.S. dollars. Intellia Therapeutics is a U.S.-based biotech company focusing on the development of therapeutics using CRISPR technology.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Intellia Therapeutics, & U.S. Securities and Exchange Commission. (February 27, 2025). Revenue of Intellia Therapeutics from 2015 to 2024 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 28, 2026, from /statistics/1097393/revenue-for-intellia-therapeutics/
Intellia Therapeutics, und U.S. Securities and Exchange Commission. "Revenue of Intellia Therapeutics from 2015 to 2024 (in million U.S. dollars)." Chart. February 27, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 28, 2026. /statistics/1097393/revenue-for-intellia-therapeutics/
Intellia Therapeutics, U.S. Securities and Exchange Commission. (2025). Revenue of Intellia Therapeutics from 2015 to 2024 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 28, 2026. /statistics/1097393/revenue-for-intellia-therapeutics/
Intellia Therapeutics, and U.S. Securities and Exchange Commission. "Revenue of Intellia Therapeutics from 2015 to 2024 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 27 Feb 2025, /statistics/1097393/revenue-for-intellia-therapeutics/
Intellia Therapeutics & U.S. Securities and Exchange Commission, Revenue of Intellia Therapeutics from 2015 to 2024 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1097393/revenue-for-intellia-therapeutics/ (last visited July 28, 2026)
Revenue of Intellia Therapeutics from 2015 to 2024 (in million U.S. dollars) [Graph], Intellia Therapeutics, & U.S. Securities and Exchange Commission, February 27, 2025. [Online]. Available: /statistics/1097393/revenue-for-intellia-therapeutics/
